Tecovirimat Patent Expiration

Tecovirimat is Used for treating human smallpox disease caused by variola virus in adults and pediatric patients. It was first introduced by Siga Technologies Inc in its drug Tpoxx on Jul 13, 2018.


Tecovirimat Patents

Given below is the list of patents protecting Tecovirimat, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Tpoxx US11890270 Polymorphic forms of ST-246 and methods of preparation Aug 08, 2032 Siga Technologies
Tpoxx US7737168 Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases Sep 04, 2031 Siga Technologies
Tpoxx US10576165 ST-246 liquid formulations and methods Aug 02, 2031 Siga Technologies
Tpoxx US9233097 ST-246 liquid formulations Aug 02, 2031 Siga Technologies
Tpoxx US9907859 ST-246 liquid formulations and methods Aug 02, 2031 Siga Technologies
Tpoxx US9339466 Polymorphic forms of ST-246 and methods of preparation Mar 23, 2031 Siga Technologies
Tpoxx US8039504 Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases Jul 23, 2027 Siga Technologies
Tpoxx US8124643 Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases Jun 18, 2024

(Expired)

Siga Technologies
Tpoxx US8530509 Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases Jun 18, 2024

(Expired)

Siga Technologies
Tpoxx US8802714 Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases Jun 18, 2024

(Expired)

Siga Technologies



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Tecovirimat's patents.

Given below is the list recent legal activities going on the following patents of Tecovirimat.

Activity Date Patent Number
Patent litigations
Patent eGrant Notification 06 Feb, 2024 US11890270
Mail Patent eGrant Notification 06 Feb, 2024 US11890270
Email Notification 06 Feb, 2024 US11890270
Recordation of Patent Grant Mailed 06 Feb, 2024 US11890270
Recordation of Patent eGrant 06 Feb, 2024 US11890270
Patent Issue Date Used in PTA Calculation 06 Feb, 2024 US11890270
Email Notification 18 Jan, 2024 US11890270
Issue Notification Mailed 17 Jan, 2024 US11890270
Application Is Considered Ready for Issue 21 Dec, 2023 US11890270
Dispatch to FDC 21 Dec, 2023 US11890270


Tecovirimat's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List